The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) achieves co-primary endpoint in its Phase 2 study of Ifenprodil

Algernon Pharmaceuticals (AGN) has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 (Ifenprodil).
Algernon Pharmaceuticals - CEO, Christopher J. Moreau.

" Algernon Pharmaceuticals (CSE:AGN) treats last patient in phase 2 IPF and chronic cough study

Algernon (AGN) has treated the last patient in its phase 2 study of IPF and chronic cough.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.

" Algernon (CSE:AGN) files meeting request with the MHRA for use of DMT in human stroke study

Algernon Pharmaceuticals (AGN) has filed a scientific advice meeting request with the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). 
The Market Herald Video

" Algernon (CSE:AGN) files pre-IND meeting request for phase 2 Ifenprodil chronic cough study

Algernon Pharmaceuticals  (AGN) has filed a pre-IND meeting request with the U.S. Food and Drug Administration.

" Algernon Pharmaceuticals (CSE:AGN) welcomes Dr. Mark Williams to the board

Algernon Pharmaceuticals (AGN) is pleased to announce that Dr. Mark Williams has been appointed as a member of the Board of Directors.

" Algernon Pharmaceuticals (CSE:AGN) welcomes Harry Bloomfield, QC. as a board director and chairman

Algernon Pharmaceuticals (AGN) has elected Harry Bloomfield as a member and Chairman of the Board of Directors.

" Algernon Pharmaceuticals (CSE:AGN) announces NP-120 (Ifenprodil) research program and appoints Dr. William North as lead consultant

Algernon Pharmaceuticals has initiated an NP-120 (Ifenprodil) small cell lung cancer (SCLC) research program.

" Algernon Pharmaceuticals (CSE:AGN) announces licensing agreement with Dartmouth College

Algernon Pharmaceuticals (AGN) has signed an exclusive licensing agreement with Dartmouth College.